Recombinant Erdr1 for Erythema in Rosacea

[Guide]

image courtesy of Int. J. Mol. Sci.

Recombinant Erdr1 (rErdr1) is an example of "Recombinant DNA (rDNA) molecules [which] are DNA molecules formed by laboratory methods of genetic recombination (such as molecular cloning) to bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome....Recombinant DNA differs from genetic recombination in that the former results from artificial methods in the test tube, while the latter is a normal biological process that results in the remixing of existing DNA sequences in essentially all organisms." Wikipedia

"Recombinant DNA, which is often shortened to rDNA, is an artificially made DNA strand that is formed by the combination of two or more gene sequences. This new combination may or may not occur naturally, but is engineered specifically for a purpose to be used in one of the many applications of recombinant DNA." New Medical Life Sciences (An example is "Recombinant DNA of the hepatitis B virus surface antigen is produced in yeast cells to be included in the vaccine." Recombinant DNA Applications, New Medical Life Sciences).

Another application of recombinant DNA is making insulin from recombinant DNA. According to the Encyclopedia Britannica in its article on Recombinant DNA Technology, states, "For example, the genes for human proteins such as growth hormone, insulin, and blood-clotting factor can be commercially manufactured."

The nutshell simple version is that rErdr1 is an artificial Erdr1 made by scientists in a lab. "Erythroid Differentiation Regulator 1 (Erdr1) is known as a hemoglobin synthesis factor which also regulates cell survival under conditions of stress." Roles of Erythroid Differentiation Regulator 1 (Erdr1) on Inflammatory Skin Diseases, International Journal of Molecular Sciences

The clinical papers below indicate that rErdr1 reduces erythema in rosacea and other examples of the effects of rErdr1. 

"Treatment with recombinant Erdr1 (rErdr1) resulted in a significant reduction of erythema, inflammatory cell infiltration (including CD4(+) and CD8(+) T cells), and microvessel density with vascular endothelial growth factor (VEGF). Taken together, our findings suggest that rErdr1 may be involved in attenuating the inflammation and angiogenesis associated with the pathogenesis of rosacea. Thus, these results provide new insight into the mechanism involved in this condition and indicate that rErdr1 could be a potential target for therapeutic intervention of rosacea." [1]

"In previous studies, erythroid differentiation regulator 1 (Erdr1) was shown to have a negative correlation with IL-18 in several inflammatory skin diseases such as melanoma and rosacea, suggesting the opposite effects with IL-18." [2]

"Treatment with Recombinant Erdr1 (r Erdr1) was also able to inhibit rosacea by inhibiting blood vessel growth or angiogenesis and preventing further infiltration of inflammatory cells. There was also significant reduction of erythema, inflammatory cell infiltration, and microvessel density with Vascular Endothelial Growth Factor (VEGF). Altogether, these studies suggest that Erdr1 has a therapeutic effect on inflammatory skin diseases, particularly psoriasis, rosacea and other skin disorders." [3]

"Erythroid differentiation regulator 1 (Erdr1) suppressed cell motility in vitro and has anti-metastatic effect in vivo on melanoma." [4]

"Taken together, these data show that rErdr1 exerts therapeutic effects on RA by inhibiting synovial fibroblast migration, suggesting that rErdr1 treatment might be an effective therapeutic approach for RA." [5]

"Erythroid Differentiation Regulator 1 (Erdr1) is known as a hemoglobin synthesis factor which also regulates cell survival under conditions of stress. In addition, previous studies have revealed the effects of Erdr1 on cancer progression and its negative correlation with interleukin (IL)-18, a pro-inflammatory cytokine. Based on this evidence, the therapeutic effects of Erdr1 have been demonstrated in several inflammatory skin diseases such as malignant skin cancer, psoriasis, and rosacea." [6]

Apparently you can purchase recombinant Erdr1 (rErdr1) or purchase from here. 

End Notes

[1] Exp Dermatol. 2015 Sep;24(9):680-5. doi: 10.1111/exd.12745. Epub 2015 Jul 14.
Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea.
Kim M, Kim KE, Jung HY, Jo H, Jeong SW, Lee J, Kim CH, Kim H, Cho D, Park HJ.

[2] J Immunol May 1, 2017, 198 (1 Supplement) 127.5;
Erdr1 is a potential therapeutic molecule in inflammatory skin disease, psoriasis
Youn Kyung Houh, Kyung Eun Kim and Daeho Cho

[3] SM Dermatology Journal, SM Group
Role of Erythroid Differentiation Regulator 1 (Erdr1) On Inflammatory Skin Disorders: A Review
Saad Sami AlSogair
Dermatology Department, Dr Layla AlOnaizi Polyclinic, Khobar, Saudi Arabia
fulltext_smdj-v3-1008.pdf

[4] Immunol Lett. 2013 Feb;150(1-2):145-51. doi: 10.1016/j.imlet.2013.01.012. Epub 2013 Jan 28.
Recombinant Erdr1 suppresses the migration and invasion ability of human gastric cancer cells, SNU-216, through the JNK pathway.
Jung MK, Houh YK, Ha S, Yang Y, Kim D, Kim TS, Yoon SR, Bang SI, Cho BJ, Lee WJ, Park H, Cho D.

[5] Oncotarget
Therapeutic effect of erythroid differentiation regulator 1 (Erdr1) on collagen-induced arthritis in DBA/1J mouse
Kyung Eun Kim, Sungryung Kim, Sunyoung Park, Younkyung Houh, Yoolhee Yang, Seung Beom Park, Sangyoon Kim, Daejin Kim5, Dae Young Hur, Seonghan Kim5, Hyun Jeong Park, Sa Ik Bang. and Daeho Cho

[6] Int. J. Mol. Sci. 2016, 17(12), 2059; doi:10.3390/ijms17122059 Review
Roles of Erythroid Differentiation Regulator 1 (Erdr1) on Inflammatory Skin Diseases
Youn Kyung Houh, Kyung Eun Kim, Hyun Jeong Park, and Daeho Cho